MNKD - MannKind Corporation
| Previous Close | 1.92 |
| Open | 1.92 |
| Bid | 1.86 x 38800 |
| Ask | 1.99 x 1100 |
| Day's Range | 1.86 - 1.99 |
| 52 Week Range | 1.09 - 6.96 |
| Volume | 1,861,334 |
| Avg. Volume | 2,184,634 |
| Market Cap | 274.449M |
| Beta | 3.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.19 |
| Earnings Date | Mar 13, 2017 - Mar 17, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
- GlobeNewswire•2 days ago
MannKind to Host Institutional Investor and Analyst Meeting
Renowned Endocrinology Expert Presenting Current Trends in Treatment and Management of Diabetes. MannKind’ s Chief Medical Officer Presenting New Afrezza ® Data Released at American Diabetes Association’ ...
- GlobeNewswire•15 days ago
MannKind Successfully Completes Phase 1 Trial of Treprostinil Technosphere for Pulmonary Arterial Hypertension Advancing Development to Next Phase
MannKind Corporation (MNKD) today announced that it has completed a Phase 1 clinical study of Treprostinil Technosphere (TreT) under an Investigational New Drug application filed with the Food and Drug Administration.
- GlobeNewswire•17 days ago
MannKind Establishes Market Price Stock Purchase Plan
WESTLAKE VILLAGE, Calif., June 05, 2018-- MannKind Corporation has established a stock purchase plan that provides MannKind’ s directors and executive officers with a way to purchase shares of common stock ...
- GlobeNewswire•last month
Detailed Research: Economic Perspectives on Churchill Downs, Nordic American Tankers, News Corporation, Aduro Biotech, MannKind, and Crane — What Drives Growth in Today's Competitive Landscape
NEW YORK, May 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Churchill ...
- Zacks•last month
Is the Options Market Predicting a Spike in MannKind (MNKD) Stock?
Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.
- Thomson Reuters StreetEvents•last month
Edited Transcript of MNKD earnings conference call or presentation 9-May-18 9:00pm GMT
Q1 2018 MannKind Corp Earnings Call
- Benzinga•last month
Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adaptimmune Therapeutics PLC – ...
- Motley Fool•last month
MannKind Q1 Results: The Good, the Bad, and the Ugly
How did the biotech company's Q1 results look? It's complicated.
- Associated Press•last month
MannKind: 1Q Earnings Snapshot
On a per-share basis, the Westlake Village, California-based company said it had a loss of 25 cents. Losses, adjusted to extinguish debt, were 24 cents per share. The biopharmaceutical company posted revenue ...
- GlobeNewswire•last month
MannKind Corporation Reports 2018 First Quarter Financial Results
Q1 2018 Afrezza Net Revenue was $3.4 million; +184% vs. Q1 2017 Q1 2018 Net Cash Used in Operating Activities was $21.7 million STAT study results accepted for presentation at American Diabetes Association’ ...
- GlobeNewswire•last month
MannKind and Cipla Enter an Exclusive Marketing and Distribution Agreement for Afrezza® in India
“Our partnership agreement with Cipla for Afrezza provides us with a long-term partner with a wealth of knowledge and experience in diabetes. Cipla is a leader across therapies in India with an established sales, marketing and distribution network. With this partnership, Cipla will leverage its strength in inhalation and extend it to diabetes therapy/portfolio,” stated Michael Castagna, Chief Executive Officer of MannKind. “The International Diabetes Federation estimates that 425 million people are currently living with diabetes worldwide, including 73 million in India.
- Motley Fool•last month
Why MannKind Corporation Stock Broke Down in April
Investors didn't take kindly to MannKind's latest secondary offering last month.
- GlobeNewswire•2 months ago
MannKind Corporation to Hold 2018 First Quarter Financial Results Conference Call on May 9, 2018
WESTLAKE VILLAGE, Calif., May 02, 2018-- MannKind Corporation will release its 2018 first quarter financial results on Wednesday, May 9, 2018 and its management will host a conference call to discuss the ...
- Simply Wall St.•2 months ago
Who Are The Top Investors In MannKind Corporation (NASDAQ:MNKD)?
In this article, I’m going to take a look at MannKind Corporation’s (NASDAQ:MNKD) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...
- GlobeNewswire•2 months ago
FDA Determines that Afrezza REMS Communication Plan Has Met Goals and REMS No Longer Necessary
WESTLAKE VILLAGE, Calif., April 25, 2018-- MannKind Corporation, focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary ...
- Benzinga•2 months ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! MannKind Corporation (NASDAQ: MNKD ) stock was trading ...
- Zacks•2 months ago
MannKind (MNKD) Enters Oversold Territory
MannKind Corporation (MNKD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
- GlobeNewswire•2 months ago
MannKind Announces Completion of Previously Announced $28.0 Million Registered Direct Offering
WESTLAKE VILLAGE, Calif., April 09, 2018-- MannKind Corporation today announced the completion of its previously announced registered direct offering of 14,000,000 shares of common stock and warrants to ...
- Motley Fool•2 months ago
Why MannKind Corporation Stock Sank Last Month
MannKind may be on its last leg.
- Zacks•2 months ago
Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock?
MannKind (MNKD) needs investors to pay close attention to the stock based on moves in the options market lately.
- Motley Fool•3 months ago
Here's Why MannKind Corporation Stock Is Tanking Today
MannKind taps investors for some much-needed capital.
- MarketWatch•3 months ago
MannKind's stock sinks after direct stock offering
Shares of MannKind Corp. sank 15% in premarket trade Friday, after the maker of inhaled therapeutic products announced a direct offering of 14 million shares, and warrants to buy an additional 14 million ...
- GlobeNewswire•3 months ago
MannKind Announces $28.0 Million Registered Direct Offering
WESTLAKE VILLAGE, Calif., April 06, 2018-- MannKind Corporation today announced the pricing of a registered direct offering of 14,000,000 shares of common stock and warrants to purchase up to an aggregate ...
- Zacks•3 months ago
Options Traders Expect Huge Moves in MannKind (MNKD) Stock
MannKind (MNKD) needs investors to pay close attention to the stock based on moves in the options market lately.
